Alignment Healthcare (ALHC) Stock: Buy, Sell, or Hold?
ALHC - Alignment Healthcare, Inc. Common Stock
$8.44
-0.07 (-0.82%)
âŧ
5d:
+2.55%
30d:
+5.63%
90d:
-57.8%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Oct 29, 2026
6d
Get Alerted When ALHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ALHC is fairly priced but lacks strong directional signals. At -24.5% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ALHC is fairly priced but lacks strong directional signals. At -24.5% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$31.64
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$19.65
57.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ALHC is currently trading at $8.44, which is considered fair relative to its 30-day fair value range of $7.46 to $9.46. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.0) compared to its historical average (30.1). Remarkably, the market is currently pricing in an annual earnings decline of 24.5% over the next few years. This pessimistic expectation contrasts with the company's recent 142.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ALHC is in a strong downtrend. Immediate support is located at $6.01, while resistance sits at $8.77.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.31 (+57.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALHC is in a strong downtrend. Immediate support is located at $6.01, while resistance sits at $8.77.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $13.31 (+57.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.46 -
$9.46
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
Protect Your Profits
Holding ALHC? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 57.7% below Wall St target ($13.31)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.46 -
$9.46
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$6.01
Resistance Level
$8.77
Current Trend
Strong Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.98
Wall Street Target
$13.31
(+57.7%)
Revenue Growth (YoY)
31.6%
Earnings Growth (YoY)
142.9%
Profit Margin
0.9%
Valuation Discount vs History
-24.5% cheaper
PE vs Historical
13.0 vs 30.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-24.5%
(market-implied from PE analysis)
1-Year Target
$7.60
(-10%)
2-Year Target
$6.84
(-19%)
3-Year Target
$6.15
(-27%)
3-Yr Target (if PE normalizes)
(PE: 13â30)
$14.26
(+69%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 43.6%)
$38.26
(+353%)
Base:
(SPY PE: 13.0, Growth: 43.6%)
$25.02
(+196%)
Bear:
(PE: 11.0, Growth: 43.6%)
$21.26
(+152%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (45x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 44.79 | Current EPS (TTM): $0.19
Bull Case
$18.72
(+122%)
Analyst growth 100.0%, PE expands to 49.3
Base Case
$17.02
(+102%)
Market implied 100.0%, PE stable at 44.8
Bear Case
$5.79
(-31%)
Severe decline -20.0%, PE contracts to 38.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.0 to 30.1
Stabilization Target:
$19.57
(+131.8%)
PE Expansion Potential:
+131.8%
Share & Embed Analysis
Last updated: October 22, 2026 6:29 AM ET
Data refreshes hourly during market hours. Next update: 7:29 AM
Data refreshes hourly during market hours. Next update: 7:29 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CVS
CVS Health Corp |
STRONG BUY
27 analysts |
$115 | 37 SELL |
|
UNH
UnitedHealth Group IncorâĻ |
STRONG BUY
26 analysts |
$477 | 32 SELL |
|
HUM
Humana Inc |
BUY
26 analysts |
$465 | 40 HOLD |
|
CI
Cigna Corp |
STRONG BUY
24 analysts |
$342 | 25 SELL |
|
ELV
Elevance Health Inc |
BUY
22 analysts |
$452 | 33 SELL |
Advanced ALHC Option Strategies
Professional options setups generated by AI based on today's ALHC price and gamma walls.
